Company: HUM
Filing Date: 2025-03-07
Form Type: DEF 14A
Source: 0001193125-25-048976
Chunk: 55

Company: HUMANA INC
Filing Date: 2025-03-07
Form: DEF 14A
Chunk 55
---
       |     |             0% |     |            15% |     |                30% |     |         |     | 174.5%                        |     | 26.2%       |
|                                 |     |           |     |                |     |                |     |                    |     |         |     | Final Performance Under Plan: |     | 95%         |

| (1) | Under the terms of the AIP, in the event that the financial measure (Adjusted EPS) results are at or below target, the non-financial measures are capped at target. |

In evaluating these results, the Committee began by noting the complex period of structural change for the Medicare Advantage (MA) industry through which the Company was operating, and the leadership of the management team in navigating these unique conditions. The Committee then reviewed the Company’s financial performance, considering that while 2024 financial results were significantly impacted by the unanticipated increase in MA medical costs trends that emerged during 2023, management had identified these trends early and successfully incorporated them into the Company’s planning for 2024, allowing the Company to slightly exceed its initial Adjusted EPS expectations while also making incremental investments to position the Company for long-term success. The Committee then noted

| 56 |     | Humana | 2025 Proxy Statement • Compensation Discussion and Analysis |

while the Company experienced strong 5% individual MA growth in 2024, these results were below the targets established prior to the 2024 Annual Enrollment Period (AEP) due to a number of factors, including lower than anticipated industry growth in 2024. Next, the Company reviewed the continued advancement of the Company’s Integrated Health strategy, in line with expectations. The Committee then reviewed the Company’s performance in advancing the strategic measures discussed above in the section titled “AIP Strategic Measures,” noting success in maintaining and advancing NPSr performance despite shifting benefit structures in the Company’s individual MA products, outperformance in driving improvements in Company’s operating leverage while also absorbing larger than anticipated incremental investments, and outperformance in achieving clinical innovation targets and positioning the Company for year-over-year improvements . Finally, the Committee noted that the AIP metrics were not subject to any automatic adjustments under the terms of the Plan and management was not recommending any exceptions or other adjustments to performance under the Plan targets. Following this review, the Committee approved a funding rate of 95% of targeted total payout.

| Named Executive Officer |     |